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Anti-cholinergic agents are generally regarded as the bronchodilator therapy of first choice in the treatment of stable 
chronic obstructive pulmonary disease (COPD), considering that they may be more effective than in inhaled 
&agonist. However, results of the authors’ recent studies conflict to some extent with this suggestion because they 
demonstrate that this is true only for short acting &agonists but not for long-acting P,-agonists. Oxitropium 
bromide is an anti-cholinergic drug that has been shown to produce a similar degree of bronchodilation to that 
obtained with ipratropium bromide, but with a longer-lasting effect. In the present study, the time course of inhaled 
oxitropium bromide bronchodilation in comparison to that of inhaled salmeterol in a group of patients with 
partially reversible COPD was evaluated. Twelve male patients with moderate to severe COPD participated in the 
study. The study had a single-bind, cross-over, randomized design. The bronchodilator activity of 5Opg salmeterol 
hydroxynaphthoate, 200 and 400 pg oxitropium bromide and placebo, which were all inhaled from a metered-dose 
inhaler, was investigated on several non-consecutive days. The highest FVC and FEV,, obtained from one or the 
other of the reproducible curves, were kept for analysis. Measurements were performed at the following times: 
immediately before inhalation of treatment, and at 15, 30, 60, 120, 180, 240, 300, 360, 480, 600 and 720 min after 
inhalation of the individual treatment. Salmeterol tended to have a delayed time to peak effect, but had a longer 
duration of effect than oxitropium. The response to salmeterol exceeded the response to 200 ,ug oxitropium for 12 h, 
but its responses were significantly (PcO.05) greater than those to 2OOpg oxitropium from 10 to 12 h. From 3 to 
12 h, salmeterol also surpassed 4OOpg oxitropium but differences were not significant (PcO.05). The mean FEV, 
area under the curve was significantly (PcO.05) larger after salmeterol when compared to 2OOpg oxitropium 
bromide, but there was no significant difference (P<O.OS) between salmeterol and 4OOpg oxitropium bromide. No 
significant changes in pulse rate, blood pressure or electrocardiograms were found among the four groups as 
compared with placebo group. These findings confirm and extend what has been demonstrated by the authors’ 
previous studies, and show that salmeterol compares conveniently with anti-cholinergic drugs in terms of effects on 
lung function at clinically recommended doses. 
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Introduction 
Recent guidelines from the American Thoracic Society (1) 
suggest the inhaled administration of an anti-cholinergic 
agent as first-line therapy in stable chronic obstructive 
pulmonary disease (COPD), considering that in most 
patients who have COPD, inhaled quaternary anti- 
cholinergic drugs offer greater bronchodilation than that 
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seen with an inhaled &agonist (2). However, results of the 
present authors’ study (3) conflict with this suggestion 
to some extent because they demonstrate that this is true 
only for short-acting &agonists, and not for long-acting 
&-agonists. The authors have recently shown that the onset 
of bronchodilation after 40,~g ipratropium bromide is 
slower than that after 2OOpg salbutamol. Moreover, ipra- 
tropium bromide produces a longer-lasting bronchodilation 
than salbutamol. In contrast, 50,~~g salmeterol, a long- 
acting &agonist, is as effective as ipratropium bromide 
in terms of the degree of bronchodilation, and has a 
longer duration of action (12 h) than anti-cholinergic 
agents (6 h). 
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TABLE 1. Anthropometric data and pulmonary function of patients 
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Patient Sex 
Age Height 
(years) (cm) 
Weight 
(kg) 
FEV, 
(1) 
FEV, 
(% predicted) 
FVC 
(1) 
FVC 
(% predicted) 
1 M 53 173 75 1.21 35 1.80 42 
2 M 57 165 71 1.58 54 2.18 59 
3 M 69 156 54 0.45 19 1.03 35 
6 M 50 163 92 0.98 32 1.42 38 
7 M 74 161 65 0.49 21 0.81 27 
8 M 58 167 71 0.45 15 0.78 21 
9 M 59 167 83 0.59 20 0.86 23 
10 M 57 157 65 0.35 13 0.58 18 
11 M 49 161 53 0.78 26 1.41 39 
12 M 69 164 63 1.18 46 1.64 50 
Oxitropium bromide is another anti-cholinergic drug. It 
has been shown to produce a similar degree of broncho- 
dilation to that obtained with ipratropium bromide, but 
with a longer-lasting effect (4). The duration of action 
would suggest that a twice daily regimen might be suitable 
for some individuals. However, a direct comparison of 
the profile of the bronchodilatory effects of oxitropium 
bromide and salmeterol over a 12-h study period in a 
controlled laboratory environment in patients with COPD 
is still lacking. 
Therefore, the time course of inhaled oxitropium bro- 
mide bronchodilation in comparison to that of inhaled 
salmeterol in a group of patients with stable COPD was 
evaluated in the present study. 
Patients and Methods 
Twelve male patients with moderate to severe COPD, but in 
a stable phase of disease, participated in the study after 
giving their informed consent. All fulfilled the criteria 
proposed by the American Thoracic Society (5): i.e. >40 
years of age; current or former smokers (> 10 pack-years) 
without a history of asthmatic attacks; reporting either 
chronic cough with or without sputum production or 
dyspnoea when walking quietly on level ground, or both; 
had had no change in symptom severity or treatment in the 
preceding 4 weeks; had shown no signs of a respiratory 
tract infection in the month preceding or during the trial; 
were not taking oral or inhaled corticosteroids for at least 
3 months; and had a FEV, <65X1 of predicted normal and 
a FVC ~70% after bronchodilators had been withheld for 
24 h. Patients with a history of asthma, allergic rhinitis 
or atopy, or with a total blood eosinophil count over 
400 mm- 3 were excluded. Table 1 outlines the baseline 
characteristics of the population studied. 
The study, which was carried out according to the rules 
of the declaration of Helsinki, was performed using a 
single-blind, balanced, cross-over, randomized design. The 
bronchodilator activity of 200 and 4OOpg oxitropium 
bromide (Boehringer Ingelheim, Florence, Italy), 50 pug 
salmeterol hydroxynaphthoate (Glaxo, Verona, Italy) and 
placebo, which were all inhaled from a metered-dose 
inhaler and holding chamber (AeroChamber) with mouth- 
piece, was investigated on several non-consecutive days. 
The four treatments were: (i) oxitropium bromide (2OOpg, 
100 pug per inhalation) plus placebo (two inhalations); (ii) 
oxitropium bromide (200 pug) plus oxitropium bromide 
(2OOpg); (iii) salmeterol (5Opg, 25 pug per inhalation) plus 
placebo; and (iv) placebo plus placebo. No oral broncho- 
dilators were permitted for 1 week before or during the 
study, whereas inhaled short-acting bronchodilator drug 
and inhaled long-acting bronchodilator agent were not 
permitted for at least 12 or 24 h prior to each test, respect- 
ively. Consumption of cola drinks, coffee or tea, and 
smoking in the hours before and during the investigation 
were also avoided. 
Spirometric testing was performed according to the pro- 
cedures described in the American Thoracic Society’s 1987 
update (5). Three acceptable forced expiratory manoeuvres 
were performed in order to obtain two reproducible results 
for FVC and FEV,. The highest FVC and FEV,, obtained 
from one or the other of the reproducible curves, were kept 
for analysis. Measurements were performed at the follow- 
ing times: immediately before inhalation of treatment, and 
at 15, 30, 60, 120, 180, 240, 300, 360,480, 600 and 720 min 
after inhalation of the individual treatment. The pulse rate 
and blood pressure were also measured after at least 5 min 
of rest prior to each spirometric measurement, and 12-lead 
electrocardiogram was taken prior to the inhalation of 
every treatment and after 3, 6 and 12 h. Patients were asked 
to note any side-effects at each time period. 
The functional indices’ increases from baseline after 
salmeterol, oxitropium bromide and placebo were assessed. 
The change in FEV, was chosen as the primary outcome 
variable to demonstrate bronchodilation (6). As an expres- 
sion of the total effect of each treatment, the areas under the 
FEV, responseetime curves (AUC) from baseline to 12 h 
were determined for each patient using the trapezoidal rule. 
Comparisons of baseline characteristics among the four 
groups were performed by ANOVA analysis and Fisher’s 
exact test. Analysis of spirometric data and those of pulse 
rate and blood pressure were performed using the Student’s 
t-test for paired variables. The time-averaged changes in the 
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FIG. 1. Mean ( f SE) absolute changes (1) in (a) FEV, and (b) FVC from baseline at different times after inhalation of 
salmeterol 50 lug (A), oxitropium 200 pug ( q ), oxitropium 400 pg (0) or placebo (0). 
12 h after drug administration, between each treatment and 
placebo, and between drugs were compared by means of 
the distribution-free cross-over analysis (7). With respect to 
the multiple testing of two lung function parameters, the 
significance level of 0.05 was considered as relevant. 
Results 
All 12 patients completed the 4-day study. There were 
no significant differences between the baseline spirometric 
values of the four treatment groups (P>O.O5). 
The mean absolute changes in FEV, and FVC following 
the four treatment regimens are shown in Fig. 1. The mean 
individual peak bronchodilation, expressed as the maxi- 
mum increase in FEV, over baseline values, occurred 
3 h after inhalation of salmeterol (range: 30-360 min), 2 h 
after inhalation of 200,~~g oxitropium (range: 15480 min) 
and 2 h after inhalation of 4OOpg oxitropium (range: 
15480 min). It must be highlighted that when individual 
subjects were considered, there was a heterogeneous 
response to the various bronchodilator regimens. However, 
when the mean duration of drug action was evaluated by 
comparing the response to placebo with those of the test 
drug, salmeterol produced a significant (BO.05) increase 
over placebo for 12 h, whereas the duration of broncho- 
dilation after 200,~g oxitropium was somewhat shorter, 
lasting for 5 and 8 h, respectively, and 4OOpg oxitropium 
sustained the action over baseline for 10 h. Salmeterol 
tended to have a delayed time to peak effect, but a longer 
duration of effect than oxitropium. The response of sal- 
meter01 exceeded that of 200 pg oxitropium for 12 h but its 
responses were significantly (P~0.05) greater than those 
of 2OOpg oxitropium from 10 to 12 h. From 3 to 12 h, 
salmeterol also surpassed 400 pg oxitropium but differences 
were not significant (BO.05). Of the salmeterol group, nine 
patients had at least 8 h 15% improvement of FEV, over 
baseline, and six patients had at least 12 h; only three 
patients of the 2OOpg oxitropium group had at least 8 h of 
FEV, increase >15% over baseline and two had at least 
12 h; six patients showed at least a 15% improvement for 
8 h and three for 12 h following inhalation of 4OOpg 
oxitropium. Analysis of the FVC responses showed similar 
effects to FEV, by the four study treatments. 
All AUC 0m,2hs for active treatments were signifi- 
cantly greater than for placebo (P>O.O5). The mean ( f SE) 
AK-,,,, for salmeterol (2.23 lh - i * 0.42) was signifi- 
cantly (P>O.O5) greater than for 2OOpg oxitropium bro- 
mide (1.13 lh- i f 0.28), and that for 400,~g oxitropium 
bromide (1.72 lh - i * 0.37) was significantly (P>O.O5) 
greater than for 2OOpg oxitropium bromide. There was 
no significant difference (P>O.O5) between salmeterol and 
400 pg oxitropium bromide AUC,-,,,s. 
No significant changes in pulse rate, blood pressure, or 
electrocardiograms were found among the three groups as 
compared with placebo group. 
No patient complained of adverse symptoms and did not 
notice any difference in the taste of the inhaler. 
Discussion 
The growing realization in recent years that airways 
obstruction in patients with COPD can be relieved signifi- 
cantly with the use of bronchodilators has changed the 
clinical approach to treating this disease. In light of the 
morbidity and mortality associated with COPD, there is 
adequate justification for physicians to use bronchodilators, 
individualized to the patient and clinical situation. 
In patients with stable COPD, the conventional dose of 
anti-cholinergic drug, two puffs, usually produces more 
bronchodilation than two puffs of P-agonist. The result is 
probably a dose effect, i.e. two puffs of anti-cholinergic 
agent support a greater fraction of the maximum effect than 
the conventional doses of P-agonists (8,9). Unfortunately, 
very few studies have compared equi-effective doses of 
anti-cholinergic agents and &-adrenoceptor agonists, which 
questions the validity of many of the studies published 
previously in the literature. Skorodin et al. (10) found doses 
of 100400,~~g oxitropium bromide were better than 15Opg 
of isoproterenol. Firth et al. (11) showed that the effect of 
2OOpg oxitropium bromide was less rapid than that of 
400,~~g fenoterol, but its duration of action was greater than 
that of fenoterol. Moreover, it has been demonstrated that 
when larger than usual doses of each agent are given to 
COPD patients, anti-cholinergics induce a similar or a 
greater degree of bronchodilation than an adrenergic agent 
(12). All these studies concluded that an anti-cholinergic 
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drug produces better bronchodilation than an adrenergic 
agent. Thus, an anti-cholinergic bronchodilator would seem 
to be the first-line agent for the therapy of stable COPD. 
In the present investigation, two puffs (2OOpg) and four 
puffs (400,~g) of oxitropium bromide were compared to 
two puffs of salmeterol (50 pug). Salmeterol elicited a greater 
peak bronchodilation and longer duration of action than 
200,~g oxitropium bromide, but four puffs of oxitropium 
bromide approximated two puffs of salmeterol in terms of 
mean peak response and duration of action. The failure to 
show a difference could be due to type II statistical error, 
i.e. insufficient statistical power in the study and, possibly, a 
study with greater power would have detected a difference. 
The authors emphasize that 2OOpg oxitropium bromide 
might be considered an insufficient dose since it has been 
demonstrated that FEV, reached a plateau only after 
administration of a cumulative dose of six puffs of oxitro- 
pium bromide (6OOpg) in patients with COPD (12) 
whereas the authors have demonstrated previously that 
5Opg salmeterol induces a good and long-lasting bron- 
chodilation, but a higher dose does not elicit additional 
improvements in partially reversible severe COPD (13). In 
any case, 200 ,ug oxitropium bromide and 50 pg salmeterol 
are dosages recommended for regular therapy (14,15). 
It is well known that minimization of the number of 
doses per day may improve compliance. Since fewer puffs of 
salmeterol are required to cause the bronchodilation which 
can be produced with oxitropium bromide, better patient 
adherence to treatment might be expected with this long- 
acting &agonist. The authors highlight that compliance to 
medication regimens is of crucial importance for manage- 
ment of COPD (16). Obviously, to confirm this, long-term 
studies will have to be performed. 
In conclusion, the present findings confirm and extend 
what has been demonstrated by previous studies (3,17), and 
show that salmeterol compares conveniently with anti- 
cholinergic drugs in terms of effects on lung function at 
clinically recommended doses. The use of salmeterol is 
expected to be associated with higher compliance by reduc- 
ing the number of inhalations utilized and thereby simplify- 
ing the regimen. In addition, this long-acting &agonist 
would appear to be the appropriate first-line broncho. 
dilator in patients with stable COPD because, at this conven- 
tional dosage, it does not induce significant cardiovascular 
adverse effects. However, the differences between salmeterol 
and oxitropium bromide during regular treatment of this 
pathological condition need to be addressed, since long-term 
coml@s&s between long-acting &agonists and anti- 
muscar%ric drug% in the treatment of COPD are absent from 
the literature. Regular assessment of the patient’s physiologi- 
cal status will determine the clinical usefulness of t;.:se 
drugs. Therefore, carefully designed studies using valid and 
reliable adherence measures are required to define their role. 
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